SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | 2026-09-02 | Open-market sell | 27 | $3K |
| Boudreau Philip P | EVP AND CFO | 2026-09-01 | Tax withholding | 388 | $43K |
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | 2026-09-01 | Tax withholding | 52 | $6K |
| Ford Robert B | CHAIRMAN AND CEO, Director | 2026-08-25 | Option exercise | 151869 | $6.7M |
| Ford Robert B | CHAIRMAN AND CEO, Director | 2026-08-25 | Option exercise | 246963 | $14.8M |
| Ford Robert B | CHAIRMAN AND CEO, Director | 2026-08-25 | Open-market sell | 218535 | $25.3M |
| Ford Robert B | CHAIRMAN AND CEO, Director | 2026-08-25 | Open-market sell | 180297 | $20.9M |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | 2026-08-12 | I | 12 | $1K |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | 2026-08-11 | Open-market sell | 5850 | $643K |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | 2026-06-30 | Tax withholding | 269 | $25K |
| Cushman Elizabeth C. | EVP, GC AND SECRETARY | 2026-06-27 | Tax withholding | 560 | $53K |
| Stratton John G | Director | 2026-05-07 | Open-market buy | 2000 | $174K |
| Moreland Mary K | EXECUTIVE VICE PRESIDENT | 2026-04-28 | I | 5314 | $502K |
| STARKS DANIEL J | Director | 2026-04-27 | Open-market buy | 10000 | $927K |
| Ahuja Nita | Director | 2026-04-24 | Grant/award | 2286 | $0 |
| Babineaux-Fontenot Claire | Director | 2026-04-24 | Grant/award | 2286 | $0 |
| Blount Sally E. | Director | 2026-04-24 | Grant/award | 2286 | $0 |
| Conroy Kevin T | Director | 2026-04-24 | Grant/award | 2286 | $0 |
| Gonzalez Patricia Paola | Director | 2026-04-24 | Grant/award | 2286 | $0 |
| Kumbier Michelle | Director | 2026-04-24 | Grant/award | 2286 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Abbott's planned $20B debt raise for the Exact Sciences acquisition represents a step-change in leverage, materially elevating refinancing and interest-cost risk from a currently manageable $12.9B base. Compounding this, newly explicit disclosures on geopolitical tensions, tariffs, and Russia-Ukraine supply chain disruptions signal a broader macro risk environment that management had not previously flagged with this specificity. Together, the two changes shift the risk profile meaningfully across both capital structure and operating exposure.
1 company-specific · 1 common-mode
Abbott plans $20B additional borrowing for Exact Sciences acquisition, materially increasing leverage and refinancing risk despite current debt declining to $12.9B.
Abbott will incur additional indebtedness in connection with the Exact Sciences acquisition, which could adversely affect its business, including decreasing its business flexibility. As of December…
New explicit disclosure of current geopolitical tensions, tariffs, Russia-Ukraine conflict impacts, and supply chain disruptions with forward-looking uncertainty about future implications.
Economic, Geopolitical and Industry Risks Changes in geopolitical and macroeconomic conditions could negatively affect Abbott’s business, financial condition, and results of operations . As a…
Abbott announced settlement of material litigation involving specialty formulas for preterm infants, resolving the Gill case (which had a $495 million jury verdict in July 2024) and claims on behalf of approximately 2,000 other individuals for an aggregate settlement amount of approximately $670 million, with approximately 1,700 pending lawsuits involving approximately 12,700 individual infants remaining.
View raw filing on EDGAR →Abbott disclosed its second-quarter 2026 financial results on July 16, 2026, including reported sales growth of 13.0%, comparable sales growth of 4.8%, GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.31. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45–$5.60. This is a standard quarterly earnings release furnished as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →